"The clinical promise of pocenbrodib, our potential best-in-class CBP/p300 inhibitor, lies not only in its remarkable efficacy in resistant prostate cancer models, but also in our sophisticated ...

Study P300-02-001 is a multicenter, open-label, dose-finding Phase 1b/2a clinical trial to confirm the safety, pharmacokinetics (PK), preliminary antitumor activity, and pharmacodynamics (PD ...

Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently ...

Under the BioVersys and GSK collaboration agreement, GSK is evaluating the early bactericidal activity (EBA) of alpibectir-ethionamide (AlpE) in a pulmonary tuberculosis (TB) trial, in combination ...

Agomab Therapeutics NV (Agomab) has announced positive interim results from 44 patients completing treatment in the ongoing ...

“Our Phase 2a trial incorporates digital health technologies to measure the effect of VENT-02 on symptoms and a comprehensive set of biomarkers that map inflammation to disease activit ...

(RTTNews) - COSCIENS Biopharma Inc. (CSCI) has initiated the Phase 2a clinical efficacy study of its avenanthramide product, aimed at managing inflammation-related conditions. Avenanthramides ...

Phase 2a results demonstrated laromestrocel (Lomecel-B) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data ...

RPESC-RPE-4W is a proprietary retinal pigment epithelium cell therapy for patients with dry age-related macular degeneration.